E
Eugene R. Bleecker
Researcher at University of Arizona
Publications - 515
Citations - 47616
Eugene R. Bleecker is an academic researcher from University of Arizona. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 104, co-authored 467 publications receiving 40181 citations. Previous affiliations of Eugene R. Bleecker include University of Aberdeen & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung,Sally E. Wenzel,Jan Brozek,Andrew Bush,Mario Castro,Peter J. Sterk,Ian M. Adcock,Eric D. Bateman,Elisabeth H. Bel,Eugene R. Bleecker,Louis-Philippe Boulet,Christopher E. Brightling,Pascal Chanez,Sven-Erik Dahlén,Ratko Djukanovic,Urs Frey,Mina Gaga,Peter G. Gibson,Qutayba Hamid,Nizar N. Jajour,Thais Mauad,Ronald L. Sorkness,W. Gerald Teague +22 more
TL;DR: Recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults and coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy are provided.
Journal ArticleDOI
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Wendy C. Moore,Deborah A. Meyers,Sally E. Wenzel,W. Gerald Teague,Huashi Li,Xingnan Li,Ralph B. D'Agostino,Mario Castro,Douglas Curran-Everett,Anne M. Fitzpatrick,Benjamin Gaston,Nizar N. Jarjour,Ronald L. Sorkness,William J. Calhoun,Kian Fan Chung,Suzy A.A. Comhair,Raed A. Dweik,Elliot Israel,Stephen P. Peters,William W. Busse,Serpil C. Erzurum,Eugene R. Bleecker +21 more
TL;DR: Five distinct clinical phenotypes of asthma have been identified using an unsupervised hierarchical cluster analysis, which supports clinical heterogeneity in asthma and the need for new approaches for the classification of disease severity in asthma.
Journal ArticleDOI
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Ian D. Pavord,Stephanie Korn,Peter H. Howarth,Eugene R. Bleecker,Roland Buhl,Oliver N. Keene,Hector Ortega,Pascal Chanez +7 more
TL;DR: Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma.
Journal ArticleDOI
The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol
TL;DR: Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects and whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown.
Journal ArticleDOI
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald,Eugene R. Bleecker,Parameswaran Nair,Stephanie Korn,Ken Ohta,Marek Lommatzsch,Gary T Ferguson,William W. Busse,Peter Barker,Stephanie Sproule,Geoffrey Gilmartin,Viktoria Werkström,Magnus Aurivillius,Mitchell Goldman +13 more
TL;DR: Benralizumab significantly reduced annual exacerbation rates and was generally well tolerated for patients with severe, uncontrolled asthma with blood eosinophils 300 cells per μL or greater, and further refine the patient population likely to receive the greatest benefit from benralsumab treatment.